Replies to post #403746 on NorthWest Biotherapeutics Inc (NWBO)

[Jack2479]

I agree all discussion will be drowned outl……timing is everything.

I can see some are already challenging what we are saying but the truth is we wouldn’t get this ridiculous line of questioning of our motives if Mgt just made it quite clear as to what the intentions are…..it looks to me to be exactly the same situation as with cognate, which we also funded.

[biosectinvestor]

The facility belongs to NWBO. Effectively Sawston will be, until the facility is fully required for NWBO’s production capacity, an incubator for other bios and for advent.

They do not have a lot of money to pump into Advent, and are not doing so. The contract terms are clear, cost of building the facilities plus 15%. The outside contractors who are doing construction are also discussed in PR’s and they worked through the pandemic and U.K. lockdown, not an easy task.

The reason to do it this way is exactly the opposite of what is suggested. NWBO does not have to raise capital at this moment to fully staff the factory or utilize all of its space or in the alternative not utilize all of the space but maintain it at full cost at the ready for DCVax-L production only.

The investors in Advent do not have to buy or lease a space in advance of receiving business. They have access to the space and if opportunities arise for contract manufacturing, they can propose the usage per their contract relationship with NWBO, and everyone gets something in return.

It’s not complicated. But the facility is not even yet certified. Once it is, I doubt they will have a huge number of other customers at the ready. But the structure is set up at this time to be ready for scale up to commercial manufacturing, but at this time NWBO’s manufacturing is only for compassionate use, paid for out of pocket, up front by patients. So the scale of initial production is not presumed to be exceedingly high until DCVax-L is approved fully by regulators for commercial use, and even then, they have some flexibility in terms of scaling production.

Many small bios find the cost of having a fully ready, fully staffed yet idle factory extremely burdensome financially. This flexible arrangement clearly allows for that burden to be symbiotically shared. These are the costs that are otherwise difficult for small bios.

So having this arrangement is certainly flexible. But not particularly troubling to me and I do not hear many people who understand the facts complaining. I hear people who are making false analogies and convoluting the facts being upset. But it looks innovative to me, and I believe it will save us shareholders in the form of less dilution and lower costs up front that save us dilution and thus cost in the long-term as well. Though that also depends on demand for Advent’s services. If there is no other demand, it may not pan out as allowing for much cost savings. So they have to market what they have access to, which is what they are doing.

So, the facility belongs fully to NWBO. Effectively Sawston will be, until the facility is fully required for NWBO’s production capacity, an incubator for other bios and for advent.